Improvements in the symptoms of olivopontocerebellar atrophy with gabapentin;Mejoría sintomática de la atrofia olivopontocerebelosa con gabapentina

Revista de Neurologia

Volumn 40, Issue 5, 2005, Pages 285-288

  Gazulla, José ^a,b   Benavente, M I ^a  

^a HOSPITAL SAN JORGE   (Spain)

^b NONE   (Spain)

Author keywords

Ataxia; Dysarthria; GABA; Gabapentin; Olivopontocerebellar atrophy; Oscillopsia

Indexed keywords

GABAPENTIN; 4 AMINOBUTYRIC ACID; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM; CEREBELLAR ATAXIA; CEREBELLUM DISEASE; CEREBROSPINAL FLUID; DYSARTHRIA; FEMALE; HUMAN; MAINTENANCE THERAPY; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; OLIVOPONTOCEREBELLAR ATROPHY; OSCILLOPSIA; SINGLE DRUG DOSE; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; VISION; MIDDLE AGED;

AMINES; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MIDDLE AGED; OLIVOPONTOCEREBELLAR ATROPHIES;

EID: 33644695314     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4005.2004448     Document Type: Article

References (32)

1. Berciano J. Olivopontocerebellar atrophy. A review of 117 cases. J Neurol Sci 1982; 53: 253-72.
2. Oppenheimer DR. Diseases of the basal ganglia, cerebellum and motor neurons. In Adams JH, Corsellis JAN, Duchen LW, eds. Greenfield's Neuropathology. Londres: Edward Arnold; 1982. p. 699-747.
3. Berciano J. Multiple system atrophy and idiopathic late-onset cerebellar ataxia. In Manto MU, Pandolfo M, eds. The cerebellum and its disorders. Cambridge: Cambridge University Press; 2002. p. 178-97.
4. Tu P, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, et al. Glial cytoplasmatic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-sinuclein. Ann Neurol 1998; 44: 415-22.
5. Gilman S, Little R, Johanns J, Heumann M, Kluin KJ, Junck L, et al. Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy. Neurology 2000; 55: 527-32.
6. Berciano J. La nosología de la atrofia olivopontocerebelosa. Revisión crítica. Arch Neurobiol 1981; 44: 163-81.
7. Kanazawa I, Kwak S, Sasaki H, Mizusawa H, Muramoto O, Yoshizawa K, et al. Studies on neurotransmitter markers and neuronal cell density in the cerebellar system in olivopontocerebellar atrophy and cortical cerebellar atrophy. J Neurol Sci 1985; 71: 193-208.
8. Perry TL, Kish SJ, Hansen S, Currier RD. Neurotransmitter amino acids in dominantly inherited cerebelar disorders. Neurology 1981; 31: 237-42.
9. Kish SJ, Perry TL, Hornykiewicz O. Benzodiazepine receptor binding in cerebellar cortex: observations in olivopontocerebellar atrophy. J Neurochem 1984; 42: 466-9.
10. Albin RL, Gilman S. Autoradiographic localization of inhibitory and excitatory amino acid neurotransmitter receptors in human normal and olivopontocerebellar atrophy cerebellar cortex. Brain Res 1990; 522: 37-45.
11. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St Laurent RT. Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography. Ann Neurol 1995; 38: 176-85.
12. Gahring LC, Rogers SW, Twyman RE. Autoantibodies to glutamate receptor subunit GluR2 in nonfamilial olivopontocerebellar degeneration. Neurology 1997; 48: 494-500.
13. Geddes JW. Glutamate receptors and excitotoxic mechanisms in Alzheimer's disease. In Peters A, Morrison JH, eds. Neurodegenerative and age-related changes in structure and function of cerebral cortex. Cerebral cortex, volumen 14. Nueva York: Kluver Academic/Plenum Publishers; 1999. p. 655-79.
14. Kish SJ, Robitaille Y, El-Awar M, Clark B, Schut L, Ball MJ, et al. Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atrophy. Neurology 1992; 42: 1573-7.
15. Rinne JO, Burn DJ, Mathias CJ, Quinn NP, Marsden CD, Brooks DJ. Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol 1995; 37: 568-73.
16. Kish SJ, Schut L, Simmons J, Gilbert J, Chang LJ, Rebbetoy M. Brain acetylcholinesterase activity is markedly reduced in dominantly-inherited olivopontocerebellar atrophy. J Neurol Neurosurg Psychiatry 1988; 51: 544-8.
17. Ogawa N, Kuroda H, Ota Z, Yamamoto M, Otsuki S. Cerebrospinal fluid gamma-aminobutiric acid variations in cerebellar ataxia. Lancet 1982; 2: 215.
18. Kuroda H, Ogawa N, Yamawaki Y, Nukina I, Ofuji T, Yamamoto M, et al. Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases. J Neurol Neurosurg Psychiatry 1982; 45: 257-60.
19. Higgins JJ, Harley-White J, Kopin IJ. Low lumbar CSF concentrations of homovanilic acid in the autosomal dominant ataxias. J Neurol Neurosurg Psychiatry 1995; 58: 760.
20. Botez MI, Young SN. Biogenic amine metabolites and thiamine in cerebrospinal fluid in heredo-degenerative ataxias. Can J Neurol Sci 2001; 28: 134-40.
21. Orozco G, Estrada R, Perry TL, Araña J, Fernández R, González-Quevedo A, et al. Dominantly inherited olivopontocerebellar atrophy from Eastern Cuba. Clinical, neuropathological, and biochemical findings. J Neurol Sci 1989; 93: 37-50.
22. Botez MI, Botez-Marquard T, Elie R, Pedraza OL, Goyette K, Lalonde R. Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study. J Neurol Neurosurg Psychiatry 1996; 61: 259-64.
23. Bonnet AM, Esteguy M, Tell G, Schechter PJ, Hardenberg J, Agid Y. A controlled study of oral vigabatrin (γ-vinilGABA) in patients with cerebellar ataxia. Can J Neurol Sci 1986; 13: 331-3.
24. Greenberg DA. Calcium channels in neurological disease. Ann Neurol 1997; 42: 275-82.
25. Cañadillas-Hidalgo FM. Perfil de seguridad y tolerabilidad de la gabapentina en dosis óptimas. Rev Neurol 2004; 39: 371-80.
26. Herranz JL. Gabapentina: mecanismos de acción en el año 2003. Rev Neurol 2003; 36: 1159-65.
27. Petroff OAC, Hyder F, Rothman DL, Mattson RH. Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. Epilepsia 2000; 41: 675-80.
28. Kuzniecky R, Ho S, Pan J, Martin R, Gilliam F, Faught E, et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 2002; 58: 368-72.
29. Gazulla J, Errea JM, Benavente I, Tordesillas C. Treatment of ataxia in cortical cerebellar atrophy with the gabaergic drug gabapentin. A preliminary study. Eur Neurol 2004; 52: 7-11.
30. Awaad Y, Sansaricq C, Mororney J, Fish I, Kyriakakos A, Snyderman SE. Baclofen in the treatment of polymyoclonus and ataxia in a patient with homocystinuria. J Child Neurol 1995; 10: 294-6.
31. Gazulla J, Benavente I. Gangliosidosis GM2 del adulto: mejoría de la ataxia con fármacos gabérgicos. Neurología 2002; 17: 157-61.
32. Möhler H, Benke D, Fritschy JM, Benson J. The benzodiazepine site of GABA A receptors. In Martin DL, Olsen RW, eds. GABA in the nervous system: the view at fifty years. Philadelphia: Lippincott, Williams & Wilkins; 2000. p. 97-112.